A newly found orthonairovirus, Wetland virus (WELV), was discovered to be pathogenic to humans, causing febrile illnesses in ...

In this secondary analysis of the MINT trial, 30-day risks for the composite outcome of death and recurrent myocardial ...

In this randomized controlled trial, patients with metabolic syndrome who underwent time-restricted eating in addition to ...

In this randomized controlled trial, in patients diagnosed with migraine, it was found that administration of a monoclonal ...

Epkinly showed an overall response rate of 82% with 62.5% of patients achieving complete response. 65% of patients had grade 1-2 cytokine release syndrome (CRS), though severe cases (grade 3) were ...

The 5-year OS rate for pembrolizumab vs placebo was 86.1% vs 81.7% with HR 0.51 (significant). 2. Immune-mediated adverse ...

Patients in the semaglutide group reported fewer heart failure events than those in the placebo group. 2. No significant ...

Afami-cel (Tecelra) is the first genetically engineered T-cell receptor therapy for synovial sarcoma Afami-cel demonstrated ...

Ticagrelor was non-inferior to DAPT for the incidence of major adverse cardiovascular and cerebrovascular events. 2.

In two cohorts from the UK Biobank and the National Health and Nutrition Examination Survey (NHANES), there was an increased ...

In a randomized double-blind placebo-controlled study, naldemedine use was associated with constipation prevention and a ...

Relutrigine resulted in a 46% reduction in seizures and seizure freedom in 30% of patients. Patients also experienced ...